- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Alimera Sciences (NASDAQ:ALIM) has announced it has expanded its partnership with Horus Pharma, one of the company’s distributors of ILUVIEN in Europe. As quoted in the press release: Following the successful launch of ILUVIEN for diabetic macular edema (DME) in France by Horus Pharma, Alimera Sciences and Horus have agreed to expand their relationship to …
Alimera Sciences (NASDAQ:ALIM) has announced it has expanded its partnership with Horus Pharma, one of the company’s distributors of ILUVIEN in Europe.
As quoted in the press release:
Following the successful launch of ILUVIEN for diabetic macular edema (DME) in France by Horus Pharma, Alimera Sciences and Horus have agreed to expand their relationship to introduce ILUVIEN for both DME and non-infectious posterior uveitis (NIPU) in the Benelux countries of Belgium, the Netherlands and Luxembourg.
Horus Pharma estimates that there are approximately 70,000 patients within the Benelux countries who may be affected by DME. With ILUVIEN approved for both DME and NIPU in the Benelux, Horus will undertake the process of applying for reimbursement in each Benelux nation for each indication over the next 12-18 months.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.